DSS, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that DSS, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $2.09M | Mar 31, 2021 |
| FY2020 | Dec 31, 2019 | $2.15M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $1.58M | Mar 31, 2020 |
| FY2018 | Dec 31, 2017 | $1.64M | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | $19.18M | Mar 6, 2018 |
| FY2015 | Dec 31, 2015 | $17.51M | Mar 30, 2016 |
| FY2015 | Dec 31, 2014 | $18.29M | Mar 30, 2016 |
| FY2014 | Dec 31, 2013 | $17.45M | Mar 30, 2015 |
| FY2013 | Dec 31, 2012 | $17.12M | Mar 26, 2014 |
| FY2012 | Dec 31, 2011 | $13.38M | Mar 6, 2013 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.76M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $19.10M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $25.93M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $28.38M | Oct 22, 2024 |
| FY2022 | Dec 31, 2021 | $20.28M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $15.37M | Aug 17, 2022 |
| FY2020 | Dec 31, 2019 | $15.55M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $18.52M | Mar 31, 2020 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2012 | Dec 31, 2012 | $5.73M | Mar 6, 2013 |
| FY2011 | Dec 31, 2011 | $4.17M | Mar 19, 2012 |
| FY2011 | Dec 31, 2010 | $3.69M | Mar 19, 2012 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($23.93M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($46.90M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($60.63M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($59.84M) | Oct 22, 2024 |
| FY2022 | Dec 31, 2021 | ($33.12M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $1.90M | Aug 17, 2022 |
| FY2020 | Dec 31, 2019 | ($2.89M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $1.46M | Mar 31, 2020 |
| FY2018 | Dec 31, 2017 | ($578.2K) | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | ($950.0K) | Mar 6, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($14.43M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($42.60M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($50.78M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($29.98M) | Oct 22, 2024 |
| FY2022 | Dec 31, 2021 | ($23.53M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($11.43M) | Aug 17, 2022 |
| FY2020 | Dec 31, 2019 | ($2.62M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($1.71M) | Mar 31, 2020 |
| FY2018 | Dec 31, 2017 | ($225.9K) | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | ($660.1K) | Mar 6, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $340.0K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $278.0K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $1.69M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $1.26M | Oct 22, 2024 |
| FY2022 | Dec 31, 2021 | $1.08M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $210.0K | Aug 17, 2022 |
| FY2020 | Dec 31, 2019 | $12.0K | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $146.0K | Mar 31, 2020 |
| FY2018 | Dec 31, 2017 | $106.0K | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | $435.0K | Mar 6, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.27M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $38.15M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $51.32M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $25.37M | Oct 22, 2024 |
| FY2022 | Dec 31, 2021 | $26.98M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $14.72M | Aug 17, 2022 |
| FY2020 | Dec 31, 2019 | $6.67M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $7.09M | Mar 31, 2020 |
| FY2018 | Mar 31, 2018 | $80.0K | Mar 15, 2019 |
| FY2018 | Dec 31, 2017 | $6.47M | Mar 15, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($9.13M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($8.76M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($19.19M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($26.95M) | Oct 22, 2024 |
| FY2022 | Dec 31, 2021 | ($9.01M) | Mar 31, 2023 |
| FY2019 | Dec 31, 2019 | ($5.34M) | Mar 31, 2020 |
| FY2019 | Dec 31, 2018 | ($1.38M) | Mar 31, 2020 |
| FY2018 | Dec 31, 2017 | ($1.29M) | Mar 15, 2019 |
| FY2012 | Dec 31, 2012 | ($3.16M) | Mar 6, 2013 |
| FY2012 | Dec 31, 2011 | ($2.12M) | Mar 6, 2013 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $133.0K | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $818.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $1.86M | Oct 22, 2024 |
| FY2022 | Dec 31, 2021 | $14.28M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $321.0K | Aug 17, 2022 |
| FY2020 | Dec 31, 2019 | $947.0K | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $1.00M | Mar 31, 2020 |
| FY2018 | Dec 31, 2017 | $958.8K | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | $269.9K | Mar 6, 2018 |
| FY2016 | Dec 31, 2015 | $157.1K | Mar 28, 2017 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $67.63M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $106.45M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $153.19M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $248.92M | Oct 22, 2024 |
| FY2022 | Dec 31, 2021 | $282.71M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $91.92M | Aug 17, 2022 |
| FY2020 | Dec 31, 2019 | $20.15M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $15.28M | Mar 31, 2020 |
| FY2018 | Dec 31, 2017 | $17.43M | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | $18.47M | Mar 6, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $58.92M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $73.74M | Mar 31, 2026 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($832.0K) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $19.94M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $63.93M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $125.56M | Oct 22, 2024 |
| FY2022 | Dec 31, 2021 | $161.78M | Mar 31, 2023 |
| FY2020 | Dec 31, 2020 | $76.55M | Mar 31, 2021 |
| FY2020 | Dec 31, 2019 | $12.30M | Mar 31, 2021 |
| FY2020 | Dec 31, 2018 | $7.58M | Mar 31, 2021 |
| FY2019 | Dec 31, 2017 | $4.79M | Mar 31, 2020 |
| FY2018 | Dec 31, 2016 | $3.28M | Mar 15, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.77M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $1.77M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $26.86M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $60.92M | Oct 22, 2024 |
| FY2022 | Dec 31, 2021 | $56.61M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $26.86M | Aug 17, 2022 |
| FY2020 | Dec 31, 2019 | $2.45M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $2.45M | Mar 31, 2020 |
| FY2018 | Dec 31, 2017 | $2.45M | Mar 15, 2019 |
| FY2018 | Dec 31, 2016 | $2.45M | Mar 15, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($327.00M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($303.07M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($256.18M) | Mar 31, 2025 |
| FY2024 | Jun 30, 2023 | $18.70M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($194.34M) | Oct 22, 2024 |
| FY2022 | Dec 31, 2021 | ($134.50M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($101.38M) | Aug 17, 2022 |
| FY2020 | Dec 31, 2019 | ($103.28M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($100.39M) | Mar 31, 2020 |
| FY2018 | Dec 31, 2017 | ($101.86M) | Mar 15, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.21M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $11.43M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $6.62M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $16.18M | Oct 22, 2024 |
| FY2022 | Dec 31, 2021 | $56.60M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $5.18M | Aug 17, 2022 |
| FY2020 | Dec 31, 2019 | $1.10M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $2.45M | Mar 31, 2020 |
| FY2018 | Dec 31, 2017 | $4.19M | Mar 15, 2019 |
| FY2018 | Dec 31, 2016 | $5.87M | Mar 15, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $44.72M | Mar 31, 2026 |
| FY2024 | Dec 31, 2024 | $57.18M | Mar 31, 2025 |
| FY2023 | Dec 31, 2023 | $55.23M | Oct 22, 2024 |
| FY2018 | Dec 31, 2018 | $2.46M | Mar 15, 2019 |
| FY2017 | Dec 31, 2017 | $2.70M | Mar 6, 2018 |
| FY2016 | Dec 31, 2016 | $3.00M | Mar 28, 2017 |
| FY2015 | Dec 31, 2015 | $3.81M | Mar 30, 2016 |
| FY2014 | Dec 31, 2014 | $8.19M | Mar 30, 2015 |
| FY2013 | Dec 31, 2013 | $4.49M | Mar 26, 2014 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | (6) | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | (8) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (6) | Oct 22, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Aug 17, 2022 |
| FY2019 | Dec 31, 2019 | 0 | Mar 31, 2020 |
| FY2019 | Dec 31, 2018 | 0 | Mar 31, 2020 |
| FY2018 | Dec 31, 2017 | 0 | Mar 15, 2019 |
| FY2014 | Dec 31, 2014 | 0 | Mar 30, 2015 |
| FY2014 | Dec 31, 2013 | 0 | Mar 30, 2015 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | (6) | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | (8) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (6) | Oct 22, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Aug 17, 2022 |
| FY2019 | Dec 31, 2019 | 0 | Mar 31, 2020 |
| FY2019 | Dec 31, 2018 | 0 | Mar 31, 2020 |
| FY2018 | Dec 31, 2017 | 0 | Mar 15, 2019 |
| FY2014 | Dec 31, 2014 | 0 | Mar 30, 2015 |
| FY2014 | Dec 31, 2013 | 0 | Mar 30, 2015 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 9.09M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 8.09M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 7.07M | Mar 31, 2025 |
| FY2024 | Dec 31, 2022 | 6.95M | Mar 31, 2025 |
| FY2022 | Dec 31, 2021 | 79.75M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 5.84M | Aug 17, 2022 |
| FY2020 | Dec 31, 2019 | 1.21M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | 17.43M | Mar 31, 2020 |
| FY2018 | Dec 31, 2017 | 16.60M | Mar 15, 2019 |
| FY2021 | Oct 31, 2017 | 333,333 | Aug 17, 2022 |